{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:13Z","timestamp":1793661013535,"version":"4.5.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejmech.2024.116159","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T02:39:10Z","timestamp":1706841550000},"page":"116159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment"],"prefix":"10.1016","volume":"267","author":[{"given":"Lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shepherd","family":"Wufoyrwoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-9380","authenticated-orcid":false,"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-4226","authenticated-orcid":false,"given":"Qihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116159_bib1","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116159_bib2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cells9071665","article-title":"DNA damage: from threat to treatment","volume":"9","author":"Carusillo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.116159_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116159_bib4","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1111\/cas.14565","article-title":"Synthetic lethality strategies: beyond BRCA1\/2 mutations in pancreatic cancer","volume":"111","author":"Hu","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2024.116159_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41594-022-00747-1","article-title":"PARP inhibition impedes the maturation of nascent DNA strands during DNA replication","volume":"29","author":"Vaitsiankova","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116159_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2024.116159_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/15384101.2017.1412147","article-title":"DNA-PK, ATM, and ATR: PIKKing on p53","volume":"17","author":"Ashley","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2024.116159_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nature03442","article-title":"Conserved modes of recruitment of ATM, ATR, and DNA-PKcs to sites of DNA damage","volume":"434","author":"Falck","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116159_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2024.116159_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","article-title":"Synthetically lethal interactions of ATM, ATR, and DNA-PKcs","volume":"4","author":"Kantidze","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2024.116159_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/genes12060925","article-title":"Kinase inhibitors of DNA-PK, ATM and ATR in combination with ionizing radiation can increase tumor cell death in HNSCC cells while sparing normal tissue cells","volume":"12","author":"Faulhaber","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2024.116159_bib12","doi-asserted-by":"crossref","first-page":"15167","DOI":"10.1073\/pnas.0504981102","article-title":"Drosophila ATM and ATR checkpoint kinases control partially redundant pathways for telomere maintenance","volume":"102","author":"Bi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116159_bib13","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116159_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 Axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116159_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib16","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/acs.oprd.0c00482","article-title":"Development and scale-up of an improved manufacturing route to the ATR inhibitor Ceralasertib","volume":"25","author":"Graham","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2024.116159_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116159_bib19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116159_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.01.026","article-title":"The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage","volume":"243","author":"Zhou","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.116159_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116159_bib22","doi-asserted-by":"crossref","first-page":"74473","DOI":"10.18632\/oncotarget.12578","article-title":"7-Ketocholesterol induces ATM\/ATR, Chk1\/Chk2, PI3K\/Akt signalings, cytotoxicity and IL-8 production in endothelial cells","volume":"7","author":"Chang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116159_bib23","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1093\/nar\/gkab628","article-title":"Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress","volume":"49","author":"Lloyd","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116159_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib26","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116159_bib27","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.116159_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116159_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3500","article-title":"First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI)","volume":"38","author":"Petrylak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116159_bib31","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib32","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1021\/acs.jmedchem.2c00324","article-title":"Structural feature analyzation strategies toward discovery of orally bioavailable PROTACs of bruton\u2019s tyrosine kinase for the treatment of lymphoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acsmedchemlett.9b00219","article-title":"Targeting IRAK4 for degradation with PROTACs","volume":"10","author":"Nunes","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116159_bib34","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic-a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116159_bib37","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib38","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116159_bib39","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-Responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib40","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy","volume":"120","author":"Shi S","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1242\/jcs.035105","article-title":"ATR signaling at a glance","volume":"122","author":"Shiotani","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2024.116159_bib42","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/rheumatology\/keab896","article-title":"Full-house nephropathy associated with high expression of SPATA5L1 due to a genetic pathogenic variant","volume":"61","author":"Carvalho","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2024.116159_bib43","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1242\/bio.018887","article-title":"Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats","volume":"5","author":"Marf\u00e0","year":"2016","journal-title":"Biol. Open"},{"key":"10.1016\/j.ejmech.2024.116159_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/09680519050110040901","article-title":"Non-LPS targets and actions of LPS binding protein (LBP)","volume":"11","author":"Schr\u00f6der","year":"2005","journal-title":"J. Endotoxin Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116159_bib46","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2174\/1389557521666210226150740","article-title":"PROTACs in treatment of cancer: a review","volume":"21","author":"Arora","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116159_bib48","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/ncomms5901","article-title":"ATR\/Chk1\/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116159_bib49","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1038\/s41598-022-09308-4","article-title":"A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress","volume":"12","author":"Egger","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116159_bib50","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1158\/0008-5472.CAN-14-2650","article-title":"Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity","volume":"74","author":"Kawasumi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/1871520620666200203160117","article-title":"Pisosterol induces G2\/M cell cycle arrest and apoptosis via the ATM\/ATR signaling pathway in human glioma cells","volume":"20","author":"Ferreira","year":"2020","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116159_bib52","first-page":"793","article-title":"H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer","volume":"12","author":"Katsuta","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116159_bib53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41419-019-1689-8","article-title":"ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation","volume":"10","author":"Gomes","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.116159_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116159_bib55","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.apsb.2021.08.025","article-title":"Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:17:36Z","timestamp":1735067856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"alternative-id":["S0223523424000394"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116159","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116159"}}